Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2010

23andMe Secures $22M in Series C Round

  • 23andMe raised over $22 million in its Series C financing round. Investors included Johnson & Johnson Development, New Enterprise Associates, and Google Ventures.

    “We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research that could ultimately make healthcare research and healthcare delivery more efficient,” says Anne Wojcicki, CEO of 23andMe.

    23andMe was founded in 2006 to focus on personal genetics. The company offers DNA analysis technologies and web-based interactive tools. Its Personal Genome Service™ enables individuals to gain insights into their ancestry and inherited traits.

    The firm officially launched its services in the U.S. in November 2007. In January 2008, it expanded into Canada and 49 European countries.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »